Related Experiment Video

Updated: May 25, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
08:21

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

[Pharmacological prevention of cardiovascular diseases]

S V Okovityĭ, A N Kulikov, K S Shulenin

    Eksperimental'Naia I Klinicheskaia Farmakologiia
    |February 1, 2012
    PubMed

    Insights

    Cardiology uses many drugs for cardiovascular disease prevention and treatment. Evidence-based medicine confirms only some pharmacological prophylaxis methods improve patient outcomes, necessitating careful drug selection.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Preventive Medicine

    Background:

    • Cardiovascular diseases necessitate diverse pharmacological interventions.
    • Recent trials highlight the importance of preventive cardiology strategies.
    • Evidence-based medicine scrutinizes the efficacy of prophylactic treatments.

    Discussion:

    • This review synthesizes data on drug efficacy in cardiology.
    • It evaluates the proven prophylactic effects of various drug classes.
    • The assessment focuses on specific patient groups and validated outcomes.

    Key Insights:

    • Not all pharmacological prophylaxis methods unequivocally improve patient prognosis.
    • Selective application of evidence-based treatments is crucial.
    • Understanding drug efficacy in specific cardiovascular patient cohorts is vital.

    Outlook:

    • Further research into targeted pharmacological interventions is warranted.
    • Optimizing preventive cardiology through validated drug therapies remains a key goal.
    • Integrating evidence-based findings into clinical practice will enhance patient care.

    Related Concept Videos

    Coronary Artery Disease IV: Preventive Measures01:26

    Coronary Artery Disease IV: Preventive Measures

    Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
    Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

    Cardiovascular Drugs: Classification based on Therapeutic Indications

    Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...